AVBP insider filings
ArriVent BioPharma, Inc. — 31 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-11-02. Screen AVBP transaction legs live →
Insider transaction summary — last 90 days
2026-08-23 to 2026-11-21, from the filings listed below: 1 insider filing (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 10.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| LaChapelle Robin — Chief Operating Officer | 1 | — | — | 10 |
Recent insider filings — ArriVent BioPharma, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-02 | 4 | LaChapelle Robin — Chief Operating Officer | Option exercise (M): 16,265 @ $3.65 · Option exercise (M): 410 @ $2.28 · Option exercise (M): 4,550 @ $2.28 · Option exercise (M): 1,820 @ $2.28 · Option exercise (M): 17,648 @ $6.24 · Option exercise (M): 410 (derivative) @ $0 · +4 more | EDGAR |
| 2026-06-22 | 4 | Parsey Merdad — Director | Grant/award (A): 13,562 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Nolet Chris — Director | Grant/award (A): 13,562 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Hohneker John — Director | Grant/award (A): 13,562 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Peterson Kristine — Director | Grant/award (A): 13,562 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | LaChapelle Robin — Chief Operating Officer | Grant/award (A): 130,000 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Lutzker Stuart — President of R&D, Director | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Kastenmayer James Paul — General Counsel | Grant/award (A): 130,000 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Kung Winston — Chief Financial Officer | Grant/award (A): 140,000 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Yao Zhengbin — President and CEO, Director | Grant/award (A): 550,000 (derivative) @ $0 | EDGAR |
| 2026-02-03 | 4 | HILLHOUSE INVESTMENT MANAGEMENT, LTD. — 10% owner HHLR ADVISORS, LTD. — 10% owner | Sale (S): 555,555 @ $23.37 | EDGAR |
| 2025-07-15 | 4 | LaChapelle Robin — Chief Operating Officer | Option exercise (M): 2,050 @ $2.28 · Option exercise (M): 2,600 @ $2.28 · Option exercise (M): 6,503 @ $2.28 · Option exercise (M): 2,050 (derivative) @ $0 · Option exercise (M): 2,600 (derivative) @ $0 · Option exercise (M): 6,503 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | Parsey Merdad — Director | Grant/award (A): 15,502 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | Nolet Chris — Director | Grant/award (A): 15,502 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | Hohneker John — Director | Grant/award (A): 15,502 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | Peterson Kristine — Director | Grant/award (A): 15,502 (derivative) @ $0 | EDGAR |
| 2025-04-29 | 4 | Parsey Merdad — Director | Grant/award (A): 28,346 (derivative) @ $0 | EDGAR |
| 2025-02-14 | 4 | Lutzker Stuart — President of R&D, Director | Grant/award (A): 120,000 (derivative) @ $0 | EDGAR |
| 2025-02-14 | 4 | LaChapelle Robin — Chief Operating Officer | Grant/award (A): 120,000 (derivative) @ $0 | EDGAR |
| 2025-02-14 | 4 | Kastenmayer James Paul — General Counsel | Grant/award (A): 102,000 (derivative) @ $0 | EDGAR |
| 2025-02-14 | 4 | Kung Winston — Chief Financial Officer | Grant/award (A): 120,000 (derivative) @ $0 | EDGAR |
| 2025-02-14 | 4 | Yao Zhengbin — President and CEO, Director | Grant/award (A): 380,000 (derivative) @ $0 | EDGAR |
| 2024-09-23 | 4 | LaChapelle Robin — Chief Operating Officer | Option exercise (M): 2,700 @ $6.24 · Option exercise (M): 2,867 @ $2.28 · Option exercise (M): 7,164 @ $2.28 · Option exercise (M): 2,471 @ $2.28 · Option exercise (M): 12,364 @ $3.65 · Option exercise (M): 2,471 (derivative) @ $0 · +4 more | EDGAR |
| 2024-05-20 | 4 | Hohneker John — Director | Grant/award (A): 29,550 (derivative) @ $0 | EDGAR |
| 2024-04-23 | 4 | Peterson Kristine — Director | Grant/award (A): 28,587 (derivative) @ $0 | EDGAR |
| 2024-02-01 | 4 | HILLHOUSE INVESTMENT MANAGEMENT, LTD. — 10% owner HHLR ADVISORS, LTD. — 10% owner | Conversion (C): 3,616,041 · Conversion (C): 313,076 · Purchase (P): 555,555 @ $18 · Conversion (C): 55,000,000 (derivative) @ $0 · Conversion (C): 4,761,903 (derivative) @ $0 | EDGAR |
| 2024-01-31 | 4 | GORDON CARL L — Director, 10% owner | Conversion (C): 821,827 · Conversion (C): 821,827 · Conversion (C): 469,615 · Conversion (C): 469,615 · Purchase (P): 222,222 @ $18 · Purchase (P): 222,222 @ $18 · +4 more | EDGAR |
| 2024-01-31 | 4 | HEALY JAMES — Director | Conversion (C): 1,252,308 · Purchase (P): 444,444 @ $18 · Conversion (C): 1,252,308 (derivative) | EDGAR |
| 2024-01-31 | 4 | ORBIMED ADVISORS LLC — Director, 10% owner OrbiMed Capital GP VIII LLC — Director, 10% owner OrbiMed Advisors IV Ltd — Director, 10% owner OrbiMed Asia GP IV, L.P. — Director, 10% owner | Conversion (C): 821,827 · Conversion (C): 821,827 · Conversion (C): 469,615 · Conversion (C): 469,615 · Purchase (P): 222,222 @ $18 · Purchase (P): 222,222 @ $18 · +4 more | EDGAR |
| 2024-01-29 | 4 | Nolet Chris — Director | Grant/award (A): 17,884 (derivative) @ $0 | EDGAR |
| 2024-01-29 | 4 | Jallal Bahija — Director | Grant/award (A): 17,884 (derivative) @ $0 | EDGAR |
Recent 8-K events — ArriVent BioPharma, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-09 | 8-K | 2.02 — Results of Operations and Financial Condition 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-26 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-19 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-13 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-06 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-12 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-22 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-11 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-11 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-17 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=AVBP returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs